245 related articles for article (PubMed ID: 28684528)
1. Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/β-Catenin Activation.
Bhagat TD; Chen S; Bartenstein M; Barlowe AT; Von Ahrens D; Choudhary GS; Tivnan P; Amin E; Marcondes AM; Sanders MA; Hoogenboezem RM; Kambhampati S; Ramachandra N; Mantzaris I; Sukrithan V; Laurence R; Lopez R; Bhagat P; Giricz O; Sohal D; Wickrema A; Yeung C; Gritsman K; Aplan P; Hochedlinger K; Yu Y; Pradhan K; Zhang J; Greally JM; Mukherjee S; Pellagatti A; Boultwood J; Will B; Steidl U; Raaijmakers MHGP; Deeg HJ; Kharas MG; Verma A
Cancer Res; 2017 Sep; 77(18):4846-4857. PubMed ID: 28684528
[TBL] [Abstract][Full Text] [Related]
2. Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes.
Falconi G; Fabiani E; Fianchi L; Criscuolo M; Raffaelli CS; Bellesi S; Hohaus S; Voso MT; D'Alò F; Leone G
Exp Hematol; 2016 Jan; 44(1):75-83.e1-4. PubMed ID: 26521017
[TBL] [Abstract][Full Text] [Related]
3. The bone marrow stem stromal imbalance--a key feature of disease progression in case of myelodysplastic mouse model.
Das M; Chatterjee S; Basak P; Das P; Pereira JA; Dutta RK; Chaklader M; Chaudhuri S; Law S
J Stem Cells; 2010; 5(2):49-64. PubMed ID: 22049615
[TBL] [Abstract][Full Text] [Related]
4. Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q.
Zhou L; Opalinska J; Sohal D; Yu Y; Mo Y; Bhagat T; Abdel-Wahab O; Fazzari M; Figueroa M; Alencar C; Zhang J; Kambhampati S; Parmar S; Nischal S; Hueck C; Suzuki M; Freidman E; Pellagatti A; Boultwood J; Steidl U; Sauthararajah Y; Yajnik V; McMahon C; Gore SD; Platanias LC; Levine R; Melnick A; Wickrema A; Greally JM; Verma A
J Biol Chem; 2011 Jul; 286(28):25211-23. PubMed ID: 21532034
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow MSCs in MDS: contribution towards dysfunctional hematopoiesis and potential targets for disease response to hypomethylating therapy.
Poon Z; Dighe N; Venkatesan SS; Cheung AMS; Fan X; Bari S; Hota M; Ghosh S; Hwang WYK
Leukemia; 2019 Jun; 33(6):1487-1500. PubMed ID: 30575819
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of WNT signaling in the bone marrow niche prevents the development of MDS in the
Stoddart A; Wang J; Hu C; Fernald AA; Davis EM; Cheng JX; Le Beau MM
Blood; 2017 Jun; 129(22):2959-2970. PubMed ID: 28348148
[TBL] [Abstract][Full Text] [Related]
7. Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes.
Varga G; Kiss J; Várkonyi J; Vas V; Farkas P; Pálóczi K; Uher F
Pathol Oncol Res; 2007; 13(4):311-9. PubMed ID: 18158566
[TBL] [Abstract][Full Text] [Related]
8. Assessment of stromal function, and its potential contribution to deregulation of hematopoiesis in the myelodysplastic syndromes.
Tauro S; Hepburn MD; Bowen DT; Pippard MJ
Haematologica; 2001 Oct; 86(10):1038-45. PubMed ID: 11602409
[TBL] [Abstract][Full Text] [Related]
9. Targeting of the bone marrow microenvironment improves outcome in a murine model of myelodysplastic syndrome.
Balderman SR; Li AJ; Hoffman CM; Frisch BJ; Goodman AN; LaMere MW; Georger MA; Evans AG; Liesveld JL; Becker MW; Calvi LM
Blood; 2016 Feb; 127(5):616-25. PubMed ID: 26637787
[TBL] [Abstract][Full Text] [Related]
10. Senescence of bone marrow mesenchymal stromal cells is accompanied by activation of p53/p21 pathway in myelodysplastic syndromes.
Fei C; Zhao Y; Guo J; Gu S; Li X; Chang C
Eur J Haematol; 2014 Dec; 93(6):476-86. PubMed ID: 24889123
[TBL] [Abstract][Full Text] [Related]
11. Aberrant promotor methylation in MDS hematopoietic cells during in vitro lineage specific differentiation is differently associated with DNMT isoforms.
Hopfer O; Komor M; Koehler IS; Freitag C; Schulze M; Hoelzer D; Thiel E; Hofmann WK
Leuk Res; 2009 Mar; 33(3):434-42. PubMed ID: 18829110
[TBL] [Abstract][Full Text] [Related]
12. SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice.
Ma Y; Cui W; Yang J; Qu J; Di C; Amin HM; Lai R; Ritz J; Krause DS; Chai L
Blood; 2006 Oct; 108(8):2726-35. PubMed ID: 16763212
[TBL] [Abstract][Full Text] [Related]
13. SETD2 deficiency accelerates MDS-associated leukemogenesis via S100a9 in NHD13 mice and predicts poor prognosis in MDS.
Chen BY; Song J; Hu CL; Chen SB; Zhang Q; Xu CH; Wu JC; Hou D; Sun M; Zhang YL; Liu N; Yu PC; Liu P; Zong LJ; Zhang JY; Dai RF; Lan F; Huang QH; Zhang SJ; Nimer SD; Chen Z; Chen SJ; Sun XJ; Wang L
Blood; 2020 Jun; 135(25):2271-2285. PubMed ID: 32202636
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of apoptosis by BCL2 prevents leukemic transformation of a murine myelodysplastic syndrome.
Slape CI; Saw J; Jowett JB; Aplan PD; Strasser A; Jane SM; Curtis DJ
Blood; 2012 Sep; 120(12):2475-83. PubMed ID: 22855610
[TBL] [Abstract][Full Text] [Related]
15. β-Catenin Is a Candidate Therapeutic Target for Myeloid Neoplasms with del(5q).
Li L; Sheng Y; Li W; Hu C; Mittal N; Tohyama K; Seba A; Zhao YY; Ozer H; Zhu T; Qian Z
Cancer Res; 2017 Aug; 77(15):4116-4126. PubMed ID: 28611040
[TBL] [Abstract][Full Text] [Related]
16. Serine protease inhibitor kunitz-type 2 is downregulated in myelodysplastic syndromes and modulates cell-cell adhesion.
Roversi FM; Lopes MR; Machado-Neto JA; Longhini AL; Duarte Ada S; Baratti MO; Palodetto B; Corrocher FA; Pericole FV; Campos Pde M; Favaro P; Traina F; Saad ST
Stem Cells Dev; 2014 May; 23(10):1109-20. PubMed ID: 24410667
[TBL] [Abstract][Full Text] [Related]
17. The Apc(min) mouse has altered hematopoietic stem cell function and provides a model for MPD/MDS.
Lane SW; Sykes SM; Al-Shahrour F; Shterental S; Paktinat M; Lo Celso C; Jesneck JL; Ebert BL; Williams DA; Gilliland DG
Blood; 2010 Apr; 115(17):3489-97. PubMed ID: 20197553
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide profiling of methylation identifies novel targets with aberrant hypermethylation and reduced expression in low-risk myelodysplastic syndromes.
del Rey M; O'Hagan K; Dellett M; Aibar S; Colyer HA; Alonso ME; Díez-Campelo M; Armstrong RN; Sharpe DJ; Gutiérrez NC; García JL; De Las Rivas J; Mills KI; Hernández-Rivas JM
Leukemia; 2013 Mar; 27(3):610-8. PubMed ID: 22936014
[TBL] [Abstract][Full Text] [Related]
19. Age-related epigenetic drift in the pathogenesis of MDS and AML.
Maegawa S; Gough SM; Watanabe-Okochi N; Lu Y; Zhang N; Castoro RJ; Estecio MR; Jelinek J; Liang S; Kitamura T; Aplan PD; Issa JP
Genome Res; 2014 Apr; 24(4):580-91. PubMed ID: 24414704
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional down-regulation of the Wnt antagonist SFRP1 in haematopoietic cells of patients with different risk types of MDS.
Reins J; Mossner M; Neumann M; Platzbecker U; Schumann C; Thiel E; Hofmann WK
Leuk Res; 2010 Dec; 34(12):1610-6. PubMed ID: 20471677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
